Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Biogen
Collaborators
NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more
NCT06180382 · Crohn's Disease
NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease
NCT07184931 · Crohn's Disease
NCT06918808 · Perianal Fistula Due to Crohn's Disease
Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions